Microbot Medical Inc. (MBOT)
NASDAQ: MBOT · Real-Time Price · USD
2.380
-0.030 (-1.24%)
At close: Mar 6, 2026, 4:00 PM EST
2.400
+0.020 (0.84%)
After-hours: Mar 6, 2026, 7:58 PM EST
Microbot Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Microbot Medical stock have an average target of 7.50, with a low estimate of 5.00 and a high estimate of 12. The average target predicts an increase of 215.13% from the current stock price of 2.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Microbot Medical stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +110.08% | Feb 10, 2026 |
| Roth Capital | Roth Capital | Strong Buy Initiates $5.5 | Strong Buy | Initiates | $5.5 | +131.09% | Dec 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +404.20% | Nov 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +404.20% | Oct 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +404.20% | Sep 11, 2025 |
Financial Forecast
Revenue This Year
102.00K
Revenue Next Year
4.39M
from 102.00K
Increased by 4,200.00%
EPS This Year
-0.31
from -0.73
EPS Next Year
-0.36
from -0.31
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 315,000 | 7.1M | ||
| Avg | 102,000 | 4.4M | ||
| Low | n/a | 2.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | - | 6,900.0% | ||
| Avg | - | 4,200.0% | ||
| Low | - | 2,686.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | -0.30 | -0.35 | ||
| Avg | -0.31 | -0.36 | ||
| Low | -0.30 | -0.36 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.